Vonex cashed up to leverage off 2SG acquisition

|

Published 18-MAY-2020 11:49 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Telecommunications innovator Vonex Limited (ASX:VN8) has received a cash inflow of $1.75 million, being the first tranche of consideration for the sale of its entitlements to iron ore production royalties derived from the Koolyanobbing Iron Ore Project.

This follows the successful completion of a CAD$13.75 million fund raising by the purchaser of the Royalty, SilverStream SEZC, a Canadian mining-focused royalty and streaming company, for the purposes of SilverStream listing on the TSXV.

While the iron ore project is no longer a core part of Vonex’s business, receipt of the initial cash consideration has strengthened the company’s cash position, and it now has cash in bank of approximately $3.5 million.

This leaves Vonex significantly funded to continue the highly-successful marketing drive in collaboration with Qantas Business Rewards, while also leveraging off the recent integration of 2SG Wholesale.

Vonex shares push up towards 12 month high

Vonex is entitled to an additional consideration from the Royalty sale of up to $750,000 based on certain production milestones at Koolyanobbing being met.

Highlighting the significance of this development, managing director Matt Fahey said, “This is a milestone event for the company, disposing of the last non-core asset for cash consideration of up to $2.5 million.

‘’These proceeds put Vonex in a very good position, with the ability now to comfortably fund our organic growth of both our direct and recently expanded wholesale businesses following the purchase of 2SG Wholesale.”

Vonex has weathered broader market volatility in good fashion for a smaller company with its shares having doubled since March, and they are now trading not far shy off their 12 month high of 15 cents.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X